Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sigma HealthcareASX:SIG -0.68%55 Debt-to-Equity is 0.41 as of Dec. 2025, which is at its 10-year median of 0.41. GuruFocus rates ASX:SIG with a GF Score™ of 55/100 and a GF Value™ of A$0.37 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 99 Medical Distribution companies, Sigma Healthcare ranks better than 56.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sigma Healthcare's Debt-to-Equity or its related term are showing as below:
ASX:SIG'
s Debt-to-Equity Range Over the Past 10 Years
Min: -93.15 Med: 0.41 Max: 0.75
Current: 0.41
During the past 13 years, the highest Debt-to-Equity Ratio of Sigma Healthcare was 0.75. The lowest was -93.15. And the median was 0.41.
ASX:SIG's Debt-to-Equity is ranked better than 56.57% of 99
companies
in the Medical Distribution industry
Industry Median: 0.48
vs ASX:SIG: 0.41
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sigma Healthcare Debt-to-Equity Related Terms
Sigma Healthcare Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sigma Healthcare's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SIG vs MCK, COR, CAH: Debt-to-Equity Comparison
For the Medical Distribution subindustry, Sigma Healthcare's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sigma Healthcare Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sigma Healthcare's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sigma Healthcare's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sigma Healthcare (ASX:SIG) has a Debt-to-Equity of 0.41 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sigma Healthcare and its competitors. This is near median its historical median of 0.41. According to the industry distribution chart, Sigma Healthcare ranks #43 out of 99 companies in the Medical Distribution industry, placing it in the top 43.4%.
Is Sigma Healthcare's Debt-to-Equity too high?
Sigma Healthcare's current Debt-to-Equity of 0.41 is near median its 10-year median of 0.41. The Medical Distribution industry median Debt-to-Equity is 0.48. Sigma Healthcare's value of 0.41 is 14.6% below this industry median. Based on the distribution chart, Sigma Healthcare ranks #43 out of 99 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sigma Healthcare has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sigma Healthcare's Debt-to-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sigma Healthcare ranks #43 out of 99 companies for Debt-to-Equity. This puts Sigma Healthcare in the upper half of its industry. The industry median Debt-to-Equity is 0.48. Sigma Healthcare's value of 0.41 is 14.6% below this benchmark. While the company's 10-year median is 0.41 vs. the industry median of 0.48, Sigma Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sigma Healthcare's current Debt-to-Equity of 0.41 is 14.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sigma Healthcare and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sigma Healthcare's current Debt-to-Equity is 0.41, which is near median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigma Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sigma Healthcare (ASX:SIG) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.37, compared to a current price of A$2.94 — trading 694.6% above its estimated fair value. The current Debt-to-Equity is 0.41, which is near median its 10-year median of 0.41 and 14.6% below the Medical Distribution industry median of 0.48. Sigma Healthcare's overall GF Score™ is 55/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sigma Healthcare (ASX:SIG), the current Debt-to-Equity is 0.41 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sigma Healthcare (ASX:SIG) Overvalued in 2026?
Based on GuruFocus' analysis, Sigma Healthcare stock appears to be overvalued.
The current stock price of A$2.94 is trading 694.6% above its estimated GF Value™ of A$0.37.
GuruFocus considers Sigma Healthcare to be Significantly Overvalued.
Key valuation signals for ASX:SIG:
Debt-to-Equity: 0.41 (near median its 10-year median of 0.41)
GF Value™: A$0.37 vs. price of A$2.94 (694.6% above fair value)
Industry Position: 14.6% below the Medical Distribution median (#43 of 99)
No single metric tells the full story. See the ASX:SIG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sigma Healthcare is Australia's largest retail pharmacy franchisor, most notably owning the Chemist Warehouse brand, which it merged with in 2025. Sigma is also Australia's largest full-line wholesaler to franchised and independent pharmacies and distributes a broad range of pharmacy products, including prescription medicines, over-the-counter products, and front of store, or FOS, products, at low prices. The group also operates in New Zealand, Ireland, China, and Dubai, has a growing private label range, and offers third-party logistics services.
55GF Score
Get the complete analysis for ASX:SIG
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SIG has been successfully added to your 
